XNASEPIX
Market cap70mUSD
Dec 24, Last price
1.59USD
1D
-2.45%
1Q
-73.89%
Jan 2017
-96.37%
IPO
-93.79%
Name
ESSA Pharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
39.33%
Rev. gr., 5y
%
Revenues
0k
Net income
0k
P
CFO
-23m
L+14.83%
Earnings
Feb 11, 2025
Profile
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | 2015‑09 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 21,207 | 32,253 | 37,082 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (21,207) | (32,253) | (37,082) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 2 | (112) | ||||||||
Tax Rate | ||||||||||
NOPAT | (21,207) | (32,254) | (36,970) | |||||||
Net income | (26,582) -24.27% | (35,103) -4.63% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 69 | 387 | ||||||||
BB yield | -0.05% | -0.48% | ||||||||
| Debt | ||||||||||
Debt current | 124 | 80 | 134 | |||||||
Long-term debt | 534 | 80 | 152 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,000 | |||||||||
Net debt | (126,102) | (147,916) | (56,790) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (22,716) | (19,782) | (28,704) | |||||||
CAPEX | ||||||||||
Cash from investing activities | 91,789 | (3,527) | (52,348) | |||||||
Cash from financing activities | 926 | (68) | 253 | |||||||
FCF | (21,434) | 78,117 | (147,101) | |||||||
| Balance | ||||||||||
Cash | 126,760 | 148,076 | 57,076 | |||||||
Long term investments | ||||||||||
Excess cash | 126,760 | 148,076 | 57,076 | |||||||
Stockholders' equity | (2,063) | 96,580 | 123,075 | |||||||
Invested Capital | 126,998 | 49,128 | 145,415 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 44,277 | 44,090 | 44,038 | |||||||
Price | 6.06 96.12% | 3.09 69.78% | 1.82 -77.25% | |||||||
Market cap | 268,319 96.95% | 136,237 69.98% | 80,150 -73.96% | |||||||
EV | 142,217 | (11,679) | 23,359 | |||||||
EBITDA | (21,207) | (32,134) | (36,960) | |||||||
EV/EBITDA | 0.36 | |||||||||
Interest | 7 | 14 | ||||||||
Interest/NOPBT | ||||||||||